Moffitt

Office Depot Launches New Podcast Series to Empower Small Business Owners

Retrieved on: 
Tuesday, September 12, 2023

Office Depot, a leading omnichannel retailer dedicated to helping its small business, home office, and education clients live more productive and organized lives through innovative products and services, today announced the launch of a new podcast series called “Imagine Success,” available now at officedepot.com/podcast and on major podcast platforms including Spotify and Apple Podcasts .

Key Points: 
  • Office Depot, a leading omnichannel retailer dedicated to helping its small business, home office, and education clients live more productive and organized lives through innovative products and services, today announced the launch of a new podcast series called “Imagine Success,” available now at officedepot.com/podcast and on major podcast platforms including Spotify and Apple Podcasts .
  • Hosted by Kevin Moffitt, executive vice president of The ODP Corporation and president of Office Depot, the podcast series features real-world strategies and stories from industry leaders and small business owners alike.
  • “At Office Depot, we’re always striving to find new, innovative ways to enable success for small business owners,” said Moffitt.
  • Visit officedepot.com/podcast to listen to the podcast and discover innovative products and helpful services designed to support small business owners.

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, September 1, 2023

The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.

Key Points: 
  • The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.
  • Cash, Cash Equivalents and Short-Term Investments: As of June 30, 2023, cash, cash equivalents and short-term investments were $49.2 million.
  • The Company expects that the combined cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second quarter of 2025.
  • Net Loss: Net loss for the three months ended June 30, 2023, was $21.5 million, compared to net income of $11.6 million for the second quarter of 2022.

Wawa to Serve as Primary Sponsor of Four NASCAR Xfinity Series Teams and Drivers in the Wawa 250 Powered by Coca-Cola at Daytona International Speedway

Retrieved on: 
Tuesday, August 22, 2023

During this year’s Wawa 250 Powered by Coca-Cola happening on August 25 at Daytona International Speedway, Wawa will be serving as primary sponsor of four NASCAR Xfinity Series teams, with each of the four drivers representing one of Wawa's brand-new Recharger energy drinks.

Key Points: 
  • During this year’s Wawa 250 Powered by Coca-Cola happening on August 25 at Daytona International Speedway, Wawa will be serving as primary sponsor of four NASCAR Xfinity Series teams, with each of the four drivers representing one of Wawa's brand-new Recharger energy drinks.
  • For the past three years, Wawa has served as the primary sponsor for the NASCAR Xfinity Series race at Daytona International Speedway.
  • The Wawa 250 Powered by Coca-Cola at Daytona isn't just another race; it's a culmination of speed, strategy, and flavor!
  • Join us under the lights of Daytona International Speedway or tune into the USA Network to experience the thrill of racing, flavored by Wawa.

pCare Smart Room of the Future Featured at the New Moffitt Cancer Center McKinley Hospital

Retrieved on: 
Tuesday, August 22, 2023

LAKE SUCCESS, N.Y. , Aug. 22, 2023 /PRNewswire/ -- pCare® announces its partnership with Moffitt Cancer Center, the only National Cancer Institute–designated Comprehensive Cancer Center based in Florida, for the ongoing integration and support of its end-to-end interactive patient care system (IPS) into the new inpatient surgical facility, Moffitt Cancer Center McKinley Hospital.

Key Points: 
  • LAKE SUCCESS, N.Y. , Aug. 22, 2023 /PRNewswire/ -- pCare® announces its partnership with Moffitt Cancer Center , the only National Cancer Institute–designated Comprehensive Cancer Center based in Florida, for the ongoing integration and support of its end-to-end interactive patient care system (IPS) into the new inpatient surgical facility, Moffitt Cancer Center McKinley Hospital .
  • "Moffitt McKinley Hospital's extensive use of our interactive patient care solutions will enhance the overall experience through compassionate care and patient, family, and clinician collaboration," shared Dave Bennett, Chief Executive Officer at pCare.
  • "We are proud to partner with Moffitt Cancer Center to boost patient experience and staff satisfaction by leveraging the healing potential of education, communication, and empowerment."
  • "Using pCare's technology, we're delivering unparalleled patient-centered care that encompasses the needs of patients and caregivers," said Christine Alvero, vice president of Hospital Operations at Moffitt McKinley Hospital.

Foundation Medicine Awards Grant to Moffitt Cancer Center and LUNGevity to Help Remove Barriers to Information About Personalized Oncology for Black Patients

Retrieved on: 
Monday, July 31, 2023

Foundation Medicine, Inc ., a pioneer in molecular profiling for cancer, today announced a grant to Moffitt Cancer Center (Moffitt) and LUNGevity Foundation to help fund their COMPASS initiative.

Key Points: 
  • Foundation Medicine, Inc ., a pioneer in molecular profiling for cancer, today announced a grant to Moffitt Cancer Center (Moffitt) and LUNGevity Foundation to help fund their COMPASS initiative.
  • Compared to white patients, Black patients are more likely to present with NSCLC and have a lower 5-year relative survival rate compared to white patients (20% vs 22%).1 This is likely due to multiple barriers that contribute to notable disparities in treatment for Black patients.
  • Foundation Medicine requested applications that included collaboration between two separate organizations, recognizing that addressing disparities in oncology care requires multi-stakeholder partnerships.
  • ​We are proud to support Moffitt and LUNGevity with their work on the COMPASS initiative to remove more barriers to Black patients’ access to personalized oncology care.”

The Leukemia & Lymphoma Society Welcomes Five Members to Board of Directors

Retrieved on: 
Monday, July 3, 2023

RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023:  Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.

Key Points: 
  • RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023: Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.
  • In his role, and with the dedication and commitment of LLS's Board of Directors, Dr. Kolb is leading the $500 million organization in its mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life for blood cancer patients and their families.
  • Leroy M. Ball: Leroy M. Ball is president and chief executive officer of Koppers and serves on the company's Board of Directors.
  • Mark J. Barrenechea: Mark J. Barrenechea joined OpenText as president and chief executive officer in January 2012 and serves as a member of the Board of Directors.

Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer

Retrieved on: 
Monday, May 22, 2023

MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC).
  • The initial goal of the Phase I trial will be to ascertain the maximum tolerated dose of eflornithine, while evaluating efficacy and then moving into a Phase II efficacy trial.
  • We anticipate data from the Phase I trial by the end of this year with a look to start the Phase II trial at the end of the year or early 2024.
  • We know that STK11 mutant tumors have reduced levels of T cells that direct immune surveillance, and they can avoid immune detection.

This Week in Health News: 10 Stories You Need to See

Retrieved on: 
Friday, May 19, 2023

NEW YORK, May 19, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • To empower families and caregivers, Modern Health's first Family Huddle will explore strategies for building positive mental health habits to help families openly discuss this important, and traditionally stigmatized topic.
  • Topics covered include the latest on gastric cancer research, such as treatment options, clinical trials, genetics, nutrition, integrative medicine, and more from the experts at Moffitt.
  • In addition to these popular releases, several must-read earnings reports crossed the wire this week, including the quarterly results for Elevation Oncology and INVO Bioscience .
  • Related Resources: Read and subscribe to our journalist- and blogger-focused blog, Beyond Bylines , for media news roundups, writing tips, upcoming events, and more.

Debbie's Dream Foundation: Curing Stomach Cancer Hosts Free Stomach Cancer Educational Symposium in Partnership with Moffitt Cancer Center

Retrieved on: 
Tuesday, May 16, 2023

FORT LAUDERDALE, Fla., May 16, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is excited to announce its upcoming Free Stomach Cancer Educational Symposium in partnership with Moffitt Cancer Center on Saturday, August 12, 2023. The symposium will take place at Moffitt's Magnolia Campus in Tampa, Florida, from 8 a.m. to 4 p.m. EST. Topics covered include the latest on gastric cancer research, such as treatment options, clinical trials, genetics, nutrition, integrative medicine, and more from the experts at Moffitt. The event will be chaired by Rutika Mehta MD, MPH, Associate Member of Moffitt's Gastrointestinal Oncology Program, Associate Professor of Oncologic Sciences at the University of South Florida, Co-Chair of GI Committee of Diversity, Inclusion, and Equity, and GI Clinical Research Assistant Medical Director at MCC. Dr. Mehta is a leading expert in gastric cancer and brings a wealth of knowledge and experience to the program.

Key Points: 
  • FORT LAUDERDALE, Fla., May 16, 2023 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is excited to announce its upcoming Free Stomach Cancer Educational Symposium in partnership with Moffitt Cancer Center on Saturday, August 12, 2023.
  • The symposium will take place at Moffitt's Magnolia Campus in Tampa, Florida, from 8 a.m. to 4 p.m. EST.
  • Topics covered include the latest on gastric cancer research, such as treatment options, clinical trials, genetics, nutrition, integrative medicine, and more from the experts at Moffitt.
  • "We are thrilled to partner with Moffitt to host this Free Stomach Cancer Educational Symposium," said Andrea Eidelman, Chief Executive Officer of DDF.

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting

Retrieved on: 
Monday, April 24, 2023

The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors.

Key Points: 
  • The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors.
  • Tumor acidosis plays a major role in tumor aggressiveness, invasion, and resistance and is an important target for novel anticancer strategies.
  • “Dyve continues to advance research in areas where our pH modulation program can unlock decades of ‘settled science’ using our proprietary delivery technology.
  • , CEO, Dyve Biosciences
    The research was published in AACR Journals and is available here: https://aacrjournals.org/cancerres/article/83/7_Supplement/2391/721916